Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 6/20 | 0.38 |
| ▸ | MGMT | P16455 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466587 | 0.90 | ADORA3 (0.46) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL11133893 | 0.86 | CDK1 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL215054 | 0.80 | PDPK1 (0.56) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL29514836 | 0.80 | PDPK1 (0.56) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16146779 | 0.80 | CDK1 (0.41) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL28770511 | 0.79 | PDPK1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16146556 | 0.79 | XDH (0.59) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16147088 | 0.79 | CYP1A2 (0.51) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16146287 | 0.76 | HTT (0.61) | ADORA3XDHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16146714 | 0.76 | GDA (0.50) | XDHMGMTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CDK1 2235/4885CCNB1 3655/4885CCNA2 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.